Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Controversy exists regarding the potential regenerative influences of incretin therapy on pancreatic β-cells versus possible adverse pancreatic proliferative effects. Examination of pancreata from age-matched organ donors with type 2 diabetes mellitus (DM) treated by incretin therapy (n = 8) or other therapy (n = 12) and nondiabetic control subjects (n = 14) reveals an ∼40% increased pancreatic mass in DM treated with incretin therapy, with both increased exocrine cell proliferation (P < 0.0001) and dysplasia (increased pancreatic intraepithelial neoplasia, P < 0.01). Pancreata in DM treated with incretin therapy were notable for α-cell hyperplasia and glucagon-expressing microadenomas (3 of 8) and a neuroendocrine tumor. β-Cell mass was reduced by ∼60% in those with DM, yet a sixfold increase was observed in incretin-treated subjects, although DM persisted. Endocrine cells costaining for insulin and glucagon were increased in DM compared with non-DM control subjects (P < 0.05) and markedly further increased by incretin therapy (P < 0.05). In conclusion, incretin therapy in humans resulted in a marked expansion of the exocrine and endocrine pancreatic compartments, the former being accompanied by increased proliferation and dysplasia and the latter by α-cell hyperplasia with the potential for evolution into neuroendocrine tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pancreatic, intestinal, and breast neoplasms were more frequently developed in rodents administered with incretin-based medications”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [56]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A decreased risk of colorectal adenomas and colorectal carcinoma is a consistent finding with a potential for a survival benefit for colorectal carcinoma.1784–1790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1788]
Experimental — accuracy not yet measuredIn the citing paper
“these results were not confirmed in human studies [56–58].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss
Thorel, F., Népote, V., Avril, I., Kohno, K., Desgraz, R., Chera, S., & Herrera, P. L. (2010) · Nature · doi:10.1038/nature08894 · Cited by 1,136
Hruban, R. H., Takaori, K., Klimstra, D. S., Adsay, N. V., Albores-Saavedra, J., Biankin, A. V., Biankin, S. A., Compton, C., Fukushima, N., Furukawa, T., et al. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000126675.59108.80 · Cited by 1,091
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Self-citationZulewski, H., Abraham, E. J., Gerlach, M. J., Daniel, P. B., Moritz, W., Müller, B., Vallejo, M., Thomas, M. K., & Habener, J. F. (2001) · Diabetes · doi:10.2337/diabetes.50.3.521 · Cited by 785
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Islet Pathology and the Pathogenesis of Type 1 and Type 2 Diabetes mellitus Revisited
Klöppel, G., Löhr, M., Habich, K., Oberholzer, M., & Heitz, P. U. (1985) · Pathology and Immunopathology Research · doi:10.1159/000156969 · Cited by 577
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure
Eizirik, D. L., Pasquali, L., & Cnop, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0355-7 · Cited by 854
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
Klemann, C., Wagner, L., Stephan, M., & von Hörsten, S. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12781 · Cited by 425
Aeffner, F., Zarella, M. D., Buchbinder, N., Bui, M. M., Goodman, M. R., Hartman, D. J., Lujan, G. M., Molani, M. A., Parwani, A. V., Lillard, K., et al. (2019) · Journal of Pathology Informatics · doi:10.4103/jpi.jpi_82_18 · Cited by 403
Diabetes recovery by age-dependent conversion of pancreatic δ-cells into insulin producers
Chera, S., Baronnier, D., Ghila, L., Cigliola, V., Jensen, J. N., Gu, G., Furuyama, K., Thorel, F., Gribble, F. M., Reimann, F., et al. (2014) · Nature · doi:10.1038/nature13633 · Cited by 410
Clinical Use of DPP-4 Inhibitors
Gallwitz, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00389 · Cited by 374
Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes
Campbell-Thompson, M., Fu, A., Kaddis, J. S., Wasserfall, C., Schatz, D. A., Pugliese, A., & Atkinson, M. A. (2016) · Diabetes · doi:10.2337/db15-0779 · Cited by 356
Self-citationEffects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Self-citationRegulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Diabetes and cancer: two diseases with obesity as a common risk factor
Garg, S. K., Maurer, H., Reed, K., & Selagamsetty, R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12124 · Cited by 275
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Pancreatic β Cell Regeneration as a Possible Therapy for Diabetes
Aguayo-Mazzucato, C., & Bonner-Weir, S. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.007 · Cited by 237
Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells
Furuyama, K., Chera, S., van Gurp, L., Oropeza, D., Ghila, L., Damond, N., Vethe, H., Paulo, J. A., Joosten, A. M., Berney, T., et al. (2019) · Nature · doi:10.1038/s41586-019-0942-8 · Cited by 241
Makrilakis, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152720 · Cited by 216
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Nauck, M. A. (2013) · Diabetes Care · doi:10.2337/dc12-2504 · Cited by 205
Maahs, D. M., Daniels, S. R., de Ferranti, S. D., Dichek, H. L., Flynn, J., Goldstein, B. I., Kelly, A. S., Nadeau, K. J., Martyn-Nemeth, P., Osganian, S. K., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000094 · Cited by 194
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Tak, Y. J., & Lee, S. Y. (2021) · The World Journal of Men's Health · doi:10.5534/wjmh.200010 · Cited by 184
Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond
Cho, Y. M., Fujita, Y., & Kieffer, T. J. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170315 · Cited by 174
Loss of β-Cell Identity Occurs in Type 2 Diabetes and Is Associated With Islet Amyloid Deposits
Spijker, H. S., Song, H., Ellenbroek, J. H., Roefs, M. M., Engelse, M. A., Bos, E., Koster, A. J., Rabelink, T. J., Hansen, B. C., Clark, A., et al. (2015) · Diabetes · doi:10.2337/db14-1752 · Cited by 172
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
Lund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 164
Demographics, Epidemiology, and Inheritance of Pancreatic Ductal Adenocarcinoma
Yeo, T. P. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.12.002 · Cited by 164
Pugliese, A., Yang, M., Kusmarteva, I., Heiple, T., Vendrame, F., Wasserfall, C., Rowe, P., Moraski, J. M., Ball, S., Jebson, L., et al. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12097 · Cited by 132
Self-citationAlterations in Beta Cell Identity in Type 1 and Type 2 Diabetes
Moin, A. S. M., & Butler, A. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1194-6 · Cited by 146
Self-citationSafety of dipeptidyl peptidase 4 inhibitors: a perspective review
Karagiannis, T., Boura, P., & Tsapas, A. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614523031 · Cited by 131
Pancreatitis-Diabetes-Pancreatic Cancer: Summary of an NIDDK-NCI Workshop
Andersen, D. K., Andren-Sandberg, Å., Duell, E. J., Goggins, M., Korc, M., Petersen, G. M., Smith, J. P., & Whitcomb, D. C. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182a9ad9d · Cited by 132
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Human Islet Morphology Revisited: Human and Rodent Islets Are Not So Different After All
Bonner‐Weir, S., Sullivan, B. A., & Weir, G. C. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415570969 · Cited by 151
Cao, C., Yang, S., & Zhou, Z. (2020) · Endocrine · doi:10.1007/s12020-020-02223-6 · Cited by 124
Deacon, C. F., & Holst, J. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.824966 · Cited by 122
Ackeifi, C., Wang, P., Karakose, E., Manning Fox, J. E., González, B. J., Liu, H., Wilson, J., Swartz, E., Berrouet, C., Li, Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw9996 · Cited by 125
Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0199-3 · Cited by 126
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Yang, Z., Lv, Y., Yu, M., Mei, M., Xiang, L., Zhao, S., & Li, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.925377 · Cited by 120
Glucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas
Waser, B., Blank, A., Karamitopoulou, E., Perren, A., & Reubi, J. C. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.113 · Cited by 119
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1006625 · Cited by 126
Mizukami, H., Takahashi, K., Inaba, W., Tsuboi, K., Osonoi, S., Yoshida, T., & Yagihashi, S. (2014) · Diabetes Care · doi:10.2337/dc13-2018 · Cited by 109
Haidinger, M., Werzowa, J., Hecking, M., Antlanger, M., Stemer, G., Pleiner, J., Kopecky, C., Kovarik, J. J., Döller, D., Pacini, G., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12518 · Cited by 110
Godinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 109
β-Cell Deficit in Obese Type 2 Diabetes, a Minor Role of β-Cell Dedifferentiation and Degranulation
Butler, A. E., Dhawan, S., Hoang, J., Cory, M., Zeng, K., Fritsch, H., Meier, J. J., Rizza, R. A., & Butler, P. C. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3566 · Cited by 109
Self-citationSitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-013-0169-1 · Cited by 117
Scheen, A. J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.978289 · Cited by 106
Cao, C., Yang, S., & Zhou, Z. (2019) · Endocrine · doi:10.1007/s12020-019-02055-z · Cited by 99
Diabetes and Cancer—An AACE/ACE Consensus Statement
Handelsman, Y., LeRoith, D., Bloomgarden, Z. T., Dagogo-Jack, S. E., EINHORN, D. F., Garber, A. J., Grunberger, G., Harrell, R. M., Gagel, R. F., Lebovitz, H. E., et al. (2013) · Endocrine Practice · doi:10.4158/ep13248.cs · Cited by 105
The therapeutic potential of GLP‐1 receptor biased agonism
Jones, B. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15497 · Cited by 98
D’Amore, C., Leva, F. S. D., Sepe, V., Renga, B., Gaudio, C. D., D’Auria, M. V., Zampella, A., Fiorucci, S., & Limongelli, V. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401873d · Cited by 99
Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
Pinto, L. C. F., Rados, D. R. V., Barkan, S. S., Leitão, C. B., & Gross, J. L. (2018) · Scientific Reports · doi:10.1038/s41598-017-19055-6 · Cited by 96
Thomsen, R. W., Pedersen, L., Møller, N., Kahlert, J., Beck-Nielsen, H., & Sørensen, H. T. (2015) · Diabetes Care · doi:10.2337/dc13-2983 · Cited by 89
Management of diabetes in older adults
Sesti, G., Antonelli Incalzi, R., Bonora, E., Consoli, A., Giaccari, A., Maggi, S., Paolisso, G., Purrello, F., Vendemiale, G., & Ferrara, N. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.007 · Cited by 84
Zhao, H., Wang, L., Wei, R., Xiu, D., Tao, M., Ke, J., Liu, Y., Yang, J., & Hong, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12291 · Cited by 88
IGFBP1 increases β‐cell regeneration by promoting α‐ to β‐cell transdifferentiation
Lü, J., Liu, K., Schulz, N., Karampelias, C., Charbord, J., Hilding, A., Rautio, L., Bertolino, P., Östenson, C., Brismar, K., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201592903 · Cited by 94
Pinto, L. C., Falcetta, M. R., Rados, D. V., Leitão, C. B., & Gross, J. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-38956-2 · Cited by 84
Of rodents and men: Species-specific glucose regulation and type 2 diabetes research
Chandrasekera, P. C. (2014) · ALTEX · doi:10.14573/1309231 · Cited by 89
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
Festa, C., Renga, B., D’Amore, C., Sepe, V., Finamore, C., De Marino, S., Carino, A., Cipriani, S., Monti, M. C., Zampella, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501273r · Cited by 84
Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study
Faillie, J.-L., Azoulay, L., Patenaude, V., Hillaire-Buys, D., & Suissa, S. (2014) · BMJ · doi:10.1136/bmj.g2780 · Cited by 83
The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
Filippatos, T. D., Athyros, V. G., & Elisaf, M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.907274 · Cited by 91
Yiu, K., & Tse, H. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.302192 · Cited by 84
Funch, D., Gydesen, H., Tornøe, K., Major‐Pedersen, A., & Chan, K. A. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12230 · Cited by 81
Steinberg, W. M., Nauck, M. A., Zinman, B., Daniels, G. H., Bergenstal, R. M., Mann, J. F. E., Steen Ravn, L., Moses, A. C., Stockner, M., Baeres, F. M. M., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000229 · Cited by 79
Zhao, H., Wei, R., Wang, L., Tian, Q., Tao, M., Ke, J., Liu, Y., Hou, W., Zhang, L., Yang, J., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00017.2014 · Cited by 77
Crona, J., Norlén, O., Antonodimitrakis, P. C., Welin, S., Stalberg, P. L. H., & Eriksson, B. K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2436 · Cited by 86
Cancer Biology and Prevention in Diabetes
Srivastava, S. P., & Goodwin, J. E. (2020) · Cells · doi:10.3390/cells9061380 · Cited by 83
Puerarin protects pancreatic β-cell survival via PI3K/Akt signaling pathway
Li, Z., Shangguan, Z., Liu, Y., Wang, J., Li, X., Yang, S., & Liu, S. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0302 · Cited by 76
Salehi, P., Hsu, I. R., Azen, C., Mittelman, S. D., Geffner, M. E., & Jeandron, D. D. (2016) · Pediatric Obesity · doi:10.1111/ijpo.12131 · Cited by 78
Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model
Abdulreda, M. H., Rodriguez‐Diaz, R., Caicedo, A., & Berggren, P. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.009 · Cited by 83
Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2035 · Cited by 71
Dipeptidyl‐peptidase‐4 inhibitors and pancreatic cancer: a cohort study
Gokhale, M., Buse, J. B., Gray, C. L., Pate, V., Marquis, M. A., & Stürmer, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12379 · Cited by 72
The French Pharmacovigilance Centers Network, Faillie, J.-L., Babai, S., Crépin, S., Bres, V., Laroche, M.-L., Le Louet, H., Petit, P., Montastruc, J.-L., & Hillaire-Buys, D. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0544-0 · Cited by 70
Raz, I., Bhatt, D. L., Hirshberg, B., Mosenzon, O., Scirica, B. M., Umez-Eronini, A., Im, K., Stahre, C., Buskila, A., Iqbal, N., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2546 · Cited by 66
Saisho, Y. (2016) · The Review of Diabetic Studies · doi:10.1900/rds.2016.13.132 · Cited by 71
Alpha-cell paracrine signaling in the regulation of beta-cell insulin secretion
Holter, M. M., Saikia, M., & Cummings, B. P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.934775 · Cited by 63
Potential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63
DPP-4 inhibitors: focus on safety
Tella, S. H., & Rendell, M. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.977863 · Cited by 63
Cefalu, W. T., Buse, J. B., Del Prato, S., Home, P. D., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 61
GLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 68
Gotfredsen, C. F., Mølck, A.-M., Thorup, I., Nyborg, N. C. B., Salanti, Z., Knudsen, L. B., & Larsen, M. O. (2014) · Diabetes · doi:10.2337/db13-1087 · Cited by 60
Irwin, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i15.1285 · Cited by 59
Ultrastructural alterations of pancreatic beta cells in human diabetes mellitus
Masini, M., Martino, L., Marselli, L., Bugliani, M., Boggi, U., Filipponi, F., Marchetti, P., & Tata, V. D. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2894 · Cited by 65
Figlioli, G., Piovani, D., Peppas, S., Pugliese, N., Hassan, C., Repici, A., Lleò, A., Aghemo, A., & Bonovas, S. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107401 · Cited by 68
Pathways governing development of stem cell‐derived pancreatic β cells: lessons from embryogenesis
Al‐Khawaga, S., Memon, B., Butler, A. E., Taheri, S., Abou‐Samra, A., & Abdelalim, E. M. (2017) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12349 · Cited by 64
Self-citationHas pancreatic damage from glucagon suppressing diabetes drugs been underplayed?
Cohen, D. R. (2013) · BMJ · doi:10.1136/bmj.f3680 · Cited by 58
Incretin Therapy and Islet Pathology: A Time for Caution
Kahn, S. E. (2013) · Diabetes · doi:10.2337/db13-0520 · Cited by 57
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
Chon, S., & Gautier, J. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.2.99 · Cited by 66
Boniol, M., Franchi, M., Bota, M., Leclercq, A., Guillaume, J., van Damme, N., Corrao, G., Autier, P., & Boyle, P. (2018) · Diabetes Care · doi:10.2337/dc17-0280 · Cited by 55
Metadata
- Authors
- Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C.
- Affiliations
- University of California, Los Angeles (US)
- Departments of Pathology and Pediatrics, College of Medicine, University of Florida, Gainesville, Florida.
- University of Florida Health (US)
- Corresponding author
- Butler, Alexandra E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-06-14
- Volume
- 62
- Issue
- 7
- Pages
- 2595-2604
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3712065
- OpenAlex
- W2137982063
- Cited by
- 457
- References
- 35
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 15 · 2023: 12 · 2022: 19 · 2021: 16 · 2020: 20 · 2019: 21 · 2018: 19 · 2017: 25 · 2016: 34 · 2015: 59 · 2014: 99 · 2013: 80
- FWCI
- 90.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- Larry L. Hillblom Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-061539, R01DK061539, DK059579, #DK077967, R01DK077967, R01DK059579)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- incretin-based therapy, beta-cell mass, pancreatic intraepithelial neoplasia, alpha cell hyperplasia, type 2 diabetes, pancreatic regeneration
- MeSH terms
- Sitagliptin Phosphate, Adenoma, Adolescent, Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Hyperplasia, Male, Middle Aged, Organ Size, Pancreas, Pyrazines, Triazoles, Neuroendocrine Tumors, Cell Proliferation, Insulin-Secreting Cells, Incretins, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.